ESMO Preceptorship on Breast Cancer Singapore November 2018
Presentations for the ESMO Preceptorship on Breast Cancer Singapore November 2018 are now available.
ESMO 2016 Congress
Copenhagen
Abstracts, slide sets and webcasts from ESMO 2016 are now available.
Neoadjuvant Osimertinib Shows ‘Promising Efficacy’ For EGFR-Mutated Resectable NSCLC
From the European Lung Cancer Congress 2022
Patients with stage II–IIIB N2 NSCLC and a relevant EGFR mutation may benefit from neoadjuvant osimertinib
NeoCOAST Points To Neoadjuvant Durvalumab Combination Potential For Early-Stage NSCLC
From the 2022 AACR Annual Meeting:
Combining neoadjuvant durvalumab with oleclumab, monalizumab or danvatirsen may offer novel strategies for early-stage NSCLC
HER3-DXd Induces CelTIL Increase In Early-Stage HR-Positive, HER2-Negative Breast Cancer
From ESMO Breast Cancer 2022:
A single dose of HER3-targeted antibody–drug conjugate induces a CelTIL response in treatment-naïve early-stage hormone receptor-positive, HER2-negative breast cancer
monarchE: 2-Year IDFS Benefit Confirmed For Clinicopathological High-Risk Breast Cancer Cohort
From ESMO Breast Cancer 2022:
Patients recruited to the monarchE trial on the basis of a high clinicopathological risk of early breast cancer recurrence derive a significant invasive disease-free survival benefit from abemaciclib use